Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Beyond convolution: Vision transformer–based modeling for histopathological classification of colorectal carcinoma.

Tanzeela Mariam Shuja, Elangovan Krishnan, Shankar Biswas et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15671

e15671 Background: Colorectal carcinoma (CRC) is a major contributor to global cancer morbidity and mortality, with histop...

Once unthinkable: Population-level changes in five-year survival for metastatic non–small cell lung cancer in the immunotherapy era.

Ujwala Koduru, Maxwell Oluwole Akanbi, Jerry Kenmoe et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20696

e20696 Background: Five-year survival in metastatic non–small cell lung cancer (NSCLC) was historically rare. The introduc...

Who receives CAR-T therapy? A national examination of racial and ethnic differences in hospitalized adults.

Aditya Keerthi Rayapureddy, Daniel Cruceta Reynoso, Shruthi Sridhar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18576

e18576 Background: CAR-T therapy has improved outcomes in hematologic malignancies but remains resource-intensive and larg...

Cancer risk and screening-preventable malignancies in transgender populations: A systematic review and meta-analysis.

Natasha Carvalho Pandolfi, Marcelle Goldner Cesca, Solange Moraes Sanches et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22522

e22522 Background: Transgender people experience health vulnerabilities shaped by structural barriers to care and differen...

Clinical utility of MRI in breast cancer diagnosed over age 70.

Alexandra Ladd, Alexandra Shapiro, Jacquelyn Amenta et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12689

e12689 Background: Previous observational studies evaluating the role of MRI in the management of breast cancer patients h...

Interpretable machine learning to identify health system levers for survival outcomes of patients with breast cancer.

Erin Feliciano, Milit S. Patel, Victoria Mango et al. Jun 01, 2026 pp. 1594-1594 10.1200/jco.2026.44.16_suppl.1594

1594 Background: Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer death among women world...

Neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of advanced gastrointestinal cancers.

Grainne M. O'Kane, Elena Elimova, Jennifer L. Spratlin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15029

e15029 Background: BOLD-100 is a ruthenium-based anticancer agent in Phase 2 development for gastrointestinal (GI) cancers...

Safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): A first-in-human phase 1/2a study (BLUESTAR).

Do-Youn Oh, Funda Meric-Bernstam, Gun Min Kim et al. Jun 01, 2026 pp. 4106-4106 10.1200/jco.2026.44.16_suppl.4106

4106 Background: B7-H4 is a transmembrane glycoprotein that negatively regulates T-cell function and is highly expressed i...

Home-based palliative care delivery by a freelancing palliative care specialist to terminally ill cancer patients in Kolkata, India: An audit of the service model.

Vivek Agarwala, Moinak Basu, MV Chandrakanth et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24045

e24045 Background: Home-based palliative care (HBPC) can provide continuity of care, symptom-management and end-of-life-ca...

Can a simple pre-mobilization complete blood count predict stem cell yield? Low-cost predictors of CD34⁺ mobilization in multiple myeloma.

Ancy Peter, Prasanth Parameswaran, Narayanankutty Edavalath Warrier et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19513

e19513 Background: Autologous hematopoietic stem cell transplantation (ASCT) remains a critical component of consolidation...

Temporal trends in oncology clinical trial complexity and duration: A retrospective analysis of 5,261 industry-sponsored trials.

Andrew J. Yang, Michael Sheen, Taemin Kim et al. Jun 01, 2026 pp. 11018-11018 10.1200/jco.2026.44.16_suppl.11018

11018 Background: Clinical trial complexity has been cited as a contributor to rising drug development costs and increasin...

Adherence to lower endoscopic surveillance in high-risk colorectal cancer populations: A meta-analysis of U.S. studies.

Anne Lincoln, Jaydeep Mahasamudram, Luigi Ricciardiello Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22536

e22536 Background: High-risk individuals, including those with a history of colorectal cancer (CRC), advanced adenomas, or...

Genomic characterization and clinical associations of rare co-mutations in <i>RAS</i> and <i>RAF</i> genes in colorectal cancer.

Li Wang, Xinyan Pan, Wanpu Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15581

e15581 Background: In colorectal cancer (CRC), mutations in RAS family genes and BRAF are typically mutually exclusive. Ho...

Feasibility and implementation of remote geriatric assessment–guided supportive care (GAIN-S) in public oncology settings.

Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Can-Lan Sun et al. Jun 01, 2026 pp. 1582-1582 10.1200/jco.2026.44.16_suppl.1582

1582 Background: The ASCO Global Guideline recommends routine geriatric assessment (GA) for adults aged ≥65 years with can...

Dual BRAF/MEK inhibition in <i>BRAF</i> <sup>V600E</sup> –mutated biliary tract cancer with exploratory histology-dependent response: A systematic review and meta-analysis.

Neel Parikh, Sannidhya Singh, Janhavi Deshpande et al. Jun 01, 2026 pp. 4108-4108 10.1200/jco.2026.44.16_suppl.4108

4108 Background: The BRAF V600E mutation defines an actionable subset of rare cancers. Metastatic BTC carries a poor progn...

Determinants of pathologic complete response in early-stage triple-negative breast cancer at a single institution.

Peter Egwom, Aparna Nanduru, Rishitha Mantri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12664

e12664 Background: Triple-negative breast cancer (TNBC) has been widely reported as having worse outcomes among Black wome...

Real-world efficacy and safety of darolutamide-based triplet therapy in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A multicenter analysis from Zhejiang province (YHCG-006 study).

Xuedong Shi, Yi Zhu, Fusheng Peng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17090

e17090 Background: The ARASENS trial established that androgen deprivation therapy (ADT) combined with Darolutamide and Do...

Stromal remodeling and neoantigen clonality as used to evaluate benefit from SIRT–nivolumab in HCC.

Josepmaria Argemí, Sandra Hervás-Stubbs, Enrique Conde et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16285

e16285 Background: The combination of selective internal radiation therapy (SIRT) and nivolumab has shown encouraging clin...

AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.

Hannah J. Glover, Farahnaz Islam, Stephanie Thiede et al. Jun 01, 2026 pp. 4210-4210 10.1200/jco.2026.44.16_suppl.4210

4210 Background: Developing predictive diagnostics for metastatic pancreatic cancer remains an unmet clinical need. Here,...

Standardized mean differences of primary outcomes found in randomized controlled trials of wellness interventions among medical trainees: A systematic review and meta-analysis.

Andrew Irving Hearn, Daniella Chrabuszcz, James Bao et al. Jun 01, 2026 pp. 9011-9011 10.1200/jco.2026.44.16_suppl.9011

9011 Background: In the era of physician shortages, wellness interventions among medical trainees is an area of ongoing re...

Clinical outcomes for patients (pts) with synchronous versus metachronous metastatic urothelial cancer (mUC) treated with enfortumab vedotin and pembrolizumab (EV-P).

Libin Yan, Lin Lin, Wadih Issa et al. Jun 01, 2026 pp. 4587-4587 10.1200/jco.2026.44.16_suppl.4587

4587 Background: Synchronous versus metachronous metastases in mUC has prognostic significance, and EV-P has emerged as st...

Real-world post-APT trial adoption of de-escalated systemic therapy and outcomes in small HER2-positive breast cancer: An NCDB analysis.

Mengni Guo, Darren Wijaya, Ami Patel et al. Jun 01, 2026 pp. 539-539 10.1200/jco.2026.44.16_suppl.539

539 Background: The APT trial shifted adjuvant management of small HER2-positive breast cancer towards paclitaxel-trastuzu...

RATIONALE-315: Post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy.

Gustavo Schvartsman, Mariano Provencio, Solange Peters et al. Jun 01, 2026 pp. 8059-8059 10.1200/jco.2026.44.16_suppl.8059

8059 Background: RATIONALE-315 (NCT04379635) compared the efficacy and safety of perioperative tislelizumab (TIS) or place...

Allogeneic CD19-targeted CAR-T therapy (BRL-301) for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Yongxian Hu, Qian Susie Tan, Mingming Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14518

e14518 Background: Despite advances in treatment, outcomes for adults with relapsed or refractory B-cell acute lymphoblast...

A multi-omic analysis of EOCRC: Divergent methylation and gene expression signatures in young patients.

Ning Jin, Selen Ayse Yilmaz, Jiangjiang Zhu et al. Jun 01, 2026 pp. 3582-3582 10.1200/jco.2026.44.16_suppl.3582

3582 Background: The incidence of early-onset colorectal cancer (EOCRC; diagnosis &lt; 50 years) is rising at an alarming...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page